We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Researchers Find First Gene Linked to Stroke

By HospiMedica staff writers
Posted on 03 Oct 2003
The first gene linked to stroke has been identified and within this gene, researchers have found haplotypes that correspond both to significantly increased risk of stroke and to significantly decreased risk. More...
The findings were reported in the September 22, 2003, online issue of Nature Genetics.

A team of investigators from deCode Genetics (Seattle, WA, USA) worked with doctors and researchers at Iceland's National University Hospital and the Icelandic Heart Association to identify the PDE4D gene and significant haplotypes by analyzing detailed genotypic data from about 1,800 Icelandic participants, including both stroke patients and unaffected relatives. Expression and functional analyses of the gene strongly suggest that PDE4D plays an important role in atherosclerosis, most likely by influencing the proliferation and migration of smooth muscle cells within arteries.

A drug that could inhibit PDE4D or any of its specific isoforms might be a useful new tool for counteracting atherosclerosis. Decode and its partner, Roche (Basel, Switzerland), have initiated medicinal chemistry on compounds they have identified as active against targets in the PDE4D pathway. Decode is also developing a DNA-based diagnostic test based on the at-risk and protective haplotypes within the PDE4D gene.

With its comprehensive population data, deCode is turning research on the genetic causes of common diseases into a growing range of products and services in gene and drug discovery, DNA-based diagnostics, pharmacogenomics, bioinformatics, and clinical trials.





Related Links:
Decode
Roche

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Absorbable Monofilament Mesh
Phasix Mesh
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.